Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Lucia Nappi MD, PhD

Lucia Nappi MD, PhD

Assistant Professor, Department of Urologic Sciences, University of British Columbia; Medical Oncologist, British Columbia Cancer; Senior Research Scientist, Vancouver Prostate Centre, Vancouver, British Columbia, Canada

Dr. Lucia Nappi is a clinician scientist, MD and PhD.

She is an assistant professor in the department of Urologic Sciences at the University of British Columbia and she hold a position as senior research scientist at the Vancouver Prostate Centre in Vancouver, BC, Canada. She is part of the medical oncology GU team at the BC Cancer in Vancouver.

She has got several grants and awards including the Michael Smith Trainee award (2015), the Southern West Oncology Group (SWOG) Young Investigator (2017), GUMOC grant and kidney cancer research network awards (2018) and most recently the Prostate Cancer Foundation Young Investigator award and the Michael Smith Foundation Health Professional Investigator award (2020).

She is the vice-chair of the SWOG Adolescent and Young Adults (AYA) committee and the co-chair of the international SWOG- S1823 cohort study and the chair of the Canadian GCC.1 equivalent study through the Canadian Cancers Trial Group (CCTGG).

She is a member of the CCTG GU and rare GU development clinical trial group.

She is one of the investigators who conceived the GUNS neoadjuvant genomic driven clinical trial in patients with high risk localized prostate cancer (Gleave PI).

She has first authored several high impact papers in the recent years, including the JCO paper (2019) that informed the S1823 clinical trial, European Urology (2020) and JCI (2020) papers.


Dr. Nappi has no relevant disclosures.